Barinthus Biotherapeutics plc.(BRNS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 15 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
BRNS Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Barinthus Biotherapeutics plc. (BRNS), a Healthcare sector company. BRNS is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 15 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q2 2026), Barinthus Biotherapeutics plc. reports net income of $-10.6M, free cash flow of $-8.1M. Top institutional holders of BRNS by reported 13-F value include M&G Plc, SC CHINA HOLDING Ltd, GLR Partners, based on the most recent SEC filings. BRNS trades on the Nasdaq exchange and files with the SEC under CIK 1828185. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BRNS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Barinthus Biotherapeutics plc. directly from SEC EDGAR.
Net Income
Q2 2026
$-10.6M
Free Cash Flow
Q2 2026
$-8.1M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-100.0% YoYNet Income
-8.8% YoYOperating Income
-3.8% YoYEPS (Diluted)
-5.8% YoYTotal Assets
-38.8% YoYTotal Debt
Op. Cash Flow
-65.8% YoYFree Cash Flow
-61.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 -100.0% | $15.0M +1766.5% | $802.0K -98.2% | $44.7M +16580.2% | $268.0K -94.4% | $4.8M |
| Net Income | $-66.4M -8.8% | $-61.1M +16.7% | $-73.3M -1473.0% | $5.3M +110.5% | $-50.9M -187.3% | $-17.7M |
| Operating Income | $-70.6M -3.8% | $-68.0M +19.0% | $-83.9M -1976.6% | $-4.0M +91.1% | $-45.2M -125.6% | $-20.0M |
| EPS (Diluted) | $-1.64 -5.8% | $-1.55 +18.8% | $-1.91 -1464.3% | $0.14 +107.1% | $-1.96 +12.5% | $-2.24 |
| Total Assets | $98.2M -38.8% | $160.3M -25.3% | $214.5M -20.6% | $270.2M -3.7% | $280.7M +454.1% | $50.7M |
| Total Debt | — | — | — | — | $159.0K | — |
| Operating Cash Flow | $-48.0M -65.8% | $-28.9M +43.2% | $-50.9M -252.9% | $-14.4M +55.7% | $-32.6M -195.5% | $-11.0M |
| Free Cash Flow | $-48.0M -61.0% | $-29.8M +47.0% | $-56.3M -173.9% | $-20.6M +39.0% | $-33.7M -197.9% | $-11.3M |
Get alerted when BRNS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Barinthus Biotherapeutics plc. including:
Top Institutional Holders of BRNS
M&G Plc
$5.2M5,197,349 shSC CHINA HOLDING Ltd
$937.5K1,420,473 shGLR Partners, LLC
$820.6K1,243,377 shDC Funds, LP
$423.9K642,204 shRangeley Capital, LLC
$122.2K185,136 shJohns Hopkins University
$80.7K122,237 shMORGAN STANLEY
$71.8K108,843 shBaird Financial Group, Inc.
$69.9K105,961 shCITADEL ADVISORS LLC
$50.7K76,754 shHighTower Advisors, LLC
$24.7K37,450 sh
| Fund | Value | Shares |
|---|---|---|
| M&G Plc | $5.2M | 5,197,349 |
| SC CHINA HOLDING Ltd | $937.5K | 1,420,473 |
| GLR Partners, LLC | $820.6K | 1,243,377 |
| DC Funds, LP | $423.9K | 642,204 |
| Rangeley Capital, LLC | $122.2K | 185,136 |
| Johns Hopkins University | $80.7K | 122,237 |
| MORGAN STANLEY | $71.8K | 108,843 |
| Baird Financial Group, Inc. | $69.9K | 105,961 |
| CITADEL ADVISORS LLC | $50.7K | 76,754 |
| HighTower Advisors, LLC | $24.7K | 37,450 |
More Healthcare Companies
View all Healthcare →Put BRNS on your watchlist
Track score changes the day Barinthus Biotherapeutics plc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is BRNS a good stock to buy?
13F Pro's AI-powered analysis of Barinthus Biotherapeutics plc. (BRNS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BRNS are available on the BRNS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BRNS is classified as a small company.
Which hedge funds own BRNS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BRNS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Barinthus Biotherapeutics plc.'s investment landscape.